Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,155,161
  • Shares Outstanding, K 107,974
  • Annual Sales, $ 258,000 K
  • Annual Income, $ -283,000 K
  • EBIT $ -375 M
  • EBITDA $ -390 M
  • 60-Month Beta 0.84
  • Price/Sales 8.37
  • Price/Cash Flow N/A
  • Price/Book 5.29

Options Overview Details

View History
  • Implied Volatility 141.25% (+9.38%)
  • Historical Volatility 72.70%
  • IV Percentile 88%
  • IV Rank 50.51%
  • IV High 220.54% on 08/08/25
  • IV Low 60.32% on 12/22/25
  • Expected Move (DTE 7) 3.42 (17.46%)
  • Put/Call Vol Ratio 0.91
  • Today's Volume 42
  • Volume Avg (30-Day) 998
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 15,463
  • Open Int (30-Day) 19,894
  • Expected Range 16.15 to 22.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.97
  • Number of Estimates 5
  • High Estimate -0.39
  • Low Estimate -1.17
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +5.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.48 +0.36%
on 02/13/26
24.59 -20.52%
on 01/15/26
-3.19 (-14.05%)
since 01/13/26
3-Month
19.33 +1.12%
on 11/14/25
26.40 -25.97%
on 12/09/25
-0.25 (-1.24%)
since 11/13/25
52-Week
6.50 +200.69%
on 04/07/25
26.40 -25.97%
on 12/09/25
+6.85 (+53.90%)
since 02/13/25

Most Recent Stories

More News
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...

RCUS : 19.43 (-2.66%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...

RCUS : 19.43 (-2.66%)
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Arcus’s highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal cell...

RCUS : 19.43 (-2.66%)
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune...

RCUS : 19.43 (-2.66%)
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

RCUS : 19.43 (-2.66%)
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development...

RCUS : 19.43 (-2.66%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and...

RCUS : 19.43 (-2.66%)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune...

RCUS : 19.43 (-2.66%)
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory...

RCUS : 19.43 (-2.66%)
Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory...

RCUS : 19.43 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 23.30
2nd Resistance Point 22.44
1st Resistance Point 21.20
Last Price 19.43
1st Support Level 19.10
2nd Support Level 18.24
3rd Support Level 17.00

See More

52-Week High 26.40
Last Price 19.43
Fibonacci 61.8% 18.80
Fibonacci 50% 16.45
Fibonacci 38.2% 14.10
52-Week Low 6.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar